Targeting DUBs to degrade oncogenic proteins.

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Therapeutics

Background:

• Targeted protein degradation is a promising strategy in oncology.
• Deubiquitinase (DUB) inhibitors represent a novel therapeutic avenue.
• Acute myeloid leukemia (AML) remains a challenging malignancy.

Discussion:

• The deubiquitinase USP10 is a potential therapeutic target in AML.
• Inhibition of USP10 leads to the degradation of key oncogenic proteins.
• Dual degradation of SYK and FLT3 has significant implications for AML treatment.

Key Insights:

• HBX19818, a novel USP10 inhibitor, induces targeted protein degradation.
• The compound effectively degrades both spleen tyrosine kinase (SYK) and FLT3.
• This dual degradation results in the death of AML cells, highlighting a new therapeutic mechanism.

Outlook:

• USP10 inhibitors like HBX19818 show potential for AML therapy.
• Further research may explore combination therapies involving DUB inhibitors.
• This approach could be extended to other hematological malignancies or solid tumors.